These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16580154)

  • 1. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report.
    Grudzinskas C; Balster RL; Gorodetzky CW; Griffiths RR; Henningfield JE; Johanson CE; Mansbach RS; McCormick CG; Schnoll SH; Strain EC; Wright C
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S77-82. PubMed ID: 16580154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Drug Formulation on Abuse Liability, Safety and Regulatory Decisions. Proceedings and abstracts of a conference, Bethesda, Maryland, USA, April 2005.
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S1-89. PubMed ID: 16563662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research design strategies to evaluate the impact of formulations on abuse liability.
    McColl S; Sellers EM
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.
    Johanson CE; Balster RL; Henningfield JE; Schuster CR; Anthony JC; Barthwell AG; Coleman JJ; Dart RC; Gorodetzky CW; O'Keeffe C; Sellers EM; Vocci F; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1(Suppl 1):S65-71. PubMed ID: 19783383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exempt preparations: Historical perspectives.
    Harris LS
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S48-51. PubMed ID: 16529881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines and methodological reviews concerning drug abuse liability assessment.
    Balster RL; Bigelow GE
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S13-40. PubMed ID: 12759195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory challenges for new formulations of controlled substances in today's environment.
    McCormick CG
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S63-7. PubMed ID: 16567060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of opioid formulations with limited diversion and abuse potential.
    Fudala PJ; Johnson RE
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S40-7. PubMed ID: 16564141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of assessment of abuse liability: US legal framework and regulatory environment.
    Rocha BA
    Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on tamper-resistant drug formulations.
    Romach MK; Schoedel KA; Sellers EM
    Drug Alcohol Depend; 2013 Jun; 130(1-3):13-23. PubMed ID: 23415386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs.
    Schuster CR
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S8-14. PubMed ID: 16483729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse deterrent formulations and the Controlled Substances Act (CSA).
    Sapienza FL
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation considerations for the development of medications with abuse potential.
    Mansbach RS; Moore RA
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives and future on testing for abuse liability in humans.
    Camí J
    Br J Addict; 1991 Dec; 86(12):1529-31. PubMed ID: 1786482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk identification, risk assessment, and risk management of abusable drug formulations.
    Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
    Cone EJ
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.
    Mastropietro DJ; Omidian H
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):193-204. PubMed ID: 25374404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO Expert Committee on Drug Dependence.
    World Health Organization
    World Health Organ Tech Rep Ser; 2016; (998):1-34. PubMed ID: 29144065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
    Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
    J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.